BioLineRX
BLRX
26 hedge funds and large institutions have $7.28M invested in BioLineRX in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
13% more funds holding
Funds holding: 23 → 26 (+3)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
46% less capital invested
Capital invested by funds: $13.6M → $7.28M (-$6.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$162K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$142K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$40.8K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$21.4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$4.55M |
| 2 |
Millennium Management
New York
|
-$105K |
| 3 |
SM
Senvest Management
New York
|
-$62.8K |
| 4 |
Morgan Stanley
New York
|
-$25.8K |
| 5 |
AL
Airain Ltd
St. Peter Port,
Guernsey
|
-$19K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| $1K | +$1.26K | +2 | New |
|
|
BC
27
Broadfin Capital
New York
| – | -$4.55M | -5,833 | Closed |
|
|
AL
28
Airain Ltd
St. Peter Port,
Guernsey
| – | -$19K | -24 | Closed |
|
29
Jane Street
New York
| – | -$16K | -20 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$2K | -3 | Closed |
|
BLRX Hedge Fund Activity: Q1 2016 in Review
26 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2016, worth a combined $7.28M — down 46% from $13.6M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BLRX positions and 4 closed out — a net gain of 3 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Alyeska Investment Group, adding an estimated $162K. The largest seller was Broadfin Capital, exiting entirely with an estimated $4.55M sold.
- 26 institutional investors held BioLineRX (BLRX) as of Q1 2016, up from 23 in Q4 2015.
- Funds reported $7.28M of BioLineRX stock for Q1 2016, down 46% quarter-over-quarter.
- 7 funds opened new BioLineRX positions in Q1 2016 and 4 closed out, a net change of +3 holders.
- The largest BioLineRX buyer in Q1 2016 was Alyeska Investment Group, an estimated $162K added.
- The largest BioLineRX seller in Q1 2016 was Broadfin Capital, an estimated $4.55M sold.
Based on aggregated 13F filings for Q1 2016.